NDA 020484 · Leo Pharma As
Innohep
Tinzaparin Sodium · Injection
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 7, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jul 14, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
636
215 Phase 3, 63 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- INNOHEP · TINZAPARIN SODIUM 20,000 IU/ML · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Tinzaparin" as an intervention, any sponsor and status, largest first.
- Study of Low Molecular Weight HeparinsPivotal-lookingStatus unknown
Herlev HospitalAcademic, hospital or other
NCT06020560 · 65,000 participants (planned) · Start Mar 23, 2023 · Primary completion Mar 23, 2025
Drug: Dalteparin Prefilled Syringe; Tinzaparin profiled syringe · For: Anticoagulant; Venous Thromboembolism; Prophylaxis and 1 more
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 9 sites in all
- Delivery and Implementation of a Randomised Crossover Trial on ThrombosisPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06937372 · 21,194 participants (planned) · Start Jul 1, 2026 · Primary completion Oct 31, 2027
Drug: Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.; Low molecular weight heparin (LMWH) · For: Hip Fractures; Venous Thromboembolism (VTE)
Sites: London, United Kingdom
- Michelangelo - Oasis 5Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00139815 · 20,078 participants · Start Apr 2003 · Primary completion Dec 2005
Drug: Fondaparinux; enoxaparin · For: Thromboembolism
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- PREVENTion of Clot in Orthopaedic TraumaPivotal-lookingCompleted
Major Extremity Trauma Research ConsortiumAcademic, hospital or other
NCT02984384 · 12,424 participants · Start Apr 24, 2017 · Primary completion Feb 18, 2022
Drug: Acetylsalicylic acid; Low Molecular Weight Heparin (LMWH) · For: Blood Clot; Trauma
Sites: Tucson, Arizona; Miami, Florida; Indianapolis, Indiana · 21 sites in all
- Thromboprophylaxis in Lower Limb ImmobilisationPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06370273 · 10,044 participants (planned) · Start Nov 12, 2024 · Primary completion Aug 31, 2028
Drug: Rivaroxaban; Apixaban and 4 more · For: Thrombosis; Injury Leg
Sites: Carshalton, United Kingdom; Hull, United Kingdom; London, United Kingdom · 5 sites in all
- The Intensive Care Platform TrialPivotal-lookingRecruiting
Anders PernerAcademic, hospital or other
NCT06667999 · 10,000 participants (planned) · Start Jun 26, 2025 · Primary completion Dec 2035
Drug: Albumin; LMWH in weight-adjusted dose and 2 more · For: Intensive Care Patients; Intensive Care Unit Patients; Critical Illness
Sites: Vienna, Austria; Aabenraa, Denmark; Aalborg, Denmark · 40 sites in all
- EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00089895 · 9,406 participants · Start Nov 1, 2004 · Primary completion Nov 1, 2008
Drug: Eptifibatide (Integrilin); Placebo · For: Myocardial Ischemia; Acute Coronary Syndrome
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review.
Abildgaard A, Madsen SA, Hvas AM · Semin Thromb Hemost 2020 · Systematic Review
- Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease: The TASC Double-Blind Controlled Randomized Clinical Trial.
Mekontso Dessap A, Habibi A, Arlet JB, et al. · Am J Respir Crit Care Med 2025 · Randomized Controlled Trial, Comparative Study
- Therapeutic equivalency of low-molecular-weight heparins.
McCart GM, Kayser SR · Ann Pharmacother 2002 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Treatments to prevent primary venous ulceration after deep venous thrombosis.
Doliner B, Jaller JA, Lopez AJ, et al. · J Vasc Surg Venous Lymphat Disord 2019 · Meta-Analysis, Systematic Review
- Haemodialysis with Tinzaparin Versus Dialysate Citrate as Anticoagulation.
Mahmood D, Stegmayr BG · Blood Purif 2018 · Clinical Trial, Comparative Study
- Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review.
Vathiotis IA, Syrigos NK, Dimakakos EP · Clin Appl Thromb Hemost 2021 · Systematic Review
Sponsor: Leo Pharma As
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.